The Eurevie study: Contrasting effect of piretanide and thiazides in mild to moderate hypertension

Therapie

Volumn 52, Issue 3, 1997, Pages 169-177

  Charansonney, O L ^a   Lievre M ^b   Laville, M ^c   Lion, L ^b   Derobert, E ^a   Visele N ^b   Decourt, S ^d   De Rusunan, M P ^a   Luciani, J ^e   Vasmant, D ^a   Boissel, J P ^b   Grunfeld J P ^a  

^a Laboratoires Hoechst   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d Société ICTA   (France)

^e Hôpital Necker ^*

Author keywords

Altizide; Double blind study; Hydrochlorothiazide; Hypertension; Loop diuretic; Piretanide; Potassium sparing diuretic; Quality of life; Spironolactone; Thiazide

Indexed keywords

ALTIZIDE; ANTIHYPERTENSIVE AGENT; CARDIOVASCULAR AGENT; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIRETANIDE; POTASSIUM; THIAZIDE DIURETIC AGENT;

ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; QUALITY OF LIFE; SPIRONOLACTONE; SULFONAMIDES;

EID: 8544273660     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
2. Hebert PR, Moser M, Mayer J, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578-581.
3. Siscovick DS, Raghunathan TE, Psaty BM et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-1857.
4. Hoes AW, Grobbee DE, Lubsen J et al. Diuretics, β-Blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123: 481-487.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
6. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412.
7. Charansonney OL, Saint-Paul D, Doan Tran D et al. Diuretics for treatment of hypertension: critical analysis of opinions of French general practitioners and cardiologists. Therapie 1996; 51: 49-55.
8. Imbs JL, Stephan D, Grima M. Diurétiques. Editions Techniques - Encycl Méd Chir (Paris, France), Thérapeutique 1994; 25-355-B-20, 11p.
9. Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of publications. BMJ 1980; 280: 905-908.
10. Clissold SP, Brogden RN. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacies. Drugs 1985; 29: 489-530.
11. Dols W, Freude J, Verho M, Rangoonwala B. A double-blind study of piretanide in the treatment of hypertension. Curr Med Res Opin 1983; 8: 649-658.
12. Gerin P, Dazord A, Boissel JP, Chifflet R. Quality of life assessment in therapeutic trials: rationale for and presentation of a more appropriate instrument. Fundam Clin Pharmacol 1992; 6: 263-276.
13. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-918.
14. Jackson JE. A user's guide to principal components. New York: Wiley, 1991.
15. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, 1992.
16. European Commission. CPMP working party on efficacy of medicinal products. Note for guidance. Biostatistical methodology in clinical trials in applications for marketing authorisations for medicinal products. Brussels, December 1994.
17. Recommandation du 12 septembre 1994 relative à la déclaration des événements graves susceptibles d'être dûs à une recherche biomédicale menées sur un médicament ou un produit assimilé. Therapie 1995; 50: 543-546.
18. Materson BJ, Oster JR, Michael UF et al. Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther 1978; 24: 192-198.
19. Goldman P. Effect of bioavailability on dose-response relationships. Am J Med 1984; November 5; 77 (5A): 47-51.
20. Skoularigis J, Strugo V, Chopamba A et al. Low dose hydrochlorothiazide (12.5 to 25 mg daily) in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring. Am J Hypertens 1995; 8: 1046-1050.
21. Genthon R, Chassard D, Derobert E et al. Changes in the frequency of micturition after repeated administration of piretanide SR (EurelixR) in healthy volunteers: a placebo-controlled study. Therapie 1995; 50: 47-52.